Summary
RA is an autoimmune, systemic, inflammatory disease that affects both small and large synovial joints in a symmetric manner. The skin, the eyes, the heart, the kidneys and the lungs ultimately. Bone and cartilage are often damaged, tendons and ligaments are weakened, and chronic inflammation leads to joint deformity and bone degeneration in the following years. RA-related systemic effects contribute to increased mortality and morbidity.
This study is designed to assess the serum levels of B cell chemokine (CXCL-13), Anti-carbamylated antibody, and to evaluate their relationships with diagnosis and severity of disease.
This case-control study obtained from Rheumatology Unit of Al-Sadr Medical City in Najaf and Al-Hussaynia General Hospital in Karbala during the period from November - 2021 to March-2022 . Sixty patients with RA who were fulfilled four or more of the 2010 American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) classification criteria for RA and sixty individuals classified as control groups. Disease activity score (DAS28-ESR), (CDAI) and Erythrocyte Sedimentation Rate(ESR) were measured, as well as rheumatoid factors (RF) were detected by latex agglutination in all participants. Anti- cyclic citrullinated peptide (ACCP), CXCL13 and Anti-CarP in the human serum samples were measured by enzyme-linked immunosorbent assay (ELISA).
Age group included in this study was 20-70. RA found high in individuals of age group <=40 years old of 45 patients at a percentage 75.0%. The mean age was 45.3±1.3 years. The results of this study showed that the RA disease is more frequent in female 46 (76.7%) than in males 14(23.3%). Female to male ratio was 3.2:1. CXCL13, Anti-CarP, Anti-CCP, and RF levels with high significantly differ among RA patients and healthy groups at p value =0.0001.CXCL13 demonstrated good specificity (83%) and high sensitivity (93%) for RA patients , while the AUC for CXCL13 was 0.88,while Anti-CarP antibodies demonstrated low sensitivity(39%) and high specificity(98%) for diagnosis of RA. On the other hand, the AUC for anti-CarP antibodies was 0.67.
Patients with RA have positive for RF; Anti-CarP were 71.7% and 36.7% respectively, while healthy group have positive for RF and Anti-CarP were 11.7% and 1.7% respectively.
The mean of ACCP antibodies level in patients was higher 95.8±32.3 in male than in female. The serum level of CXCL13 shows no a significant difference (P =0.7) between male and female with means 1.02±0.15 and 0.8±0.03 respectively, while there is no significant difference in anti-CarP or RF between male and female (P value= 0.9; 0.8) respectively. In addition, there was no significant difference at P value=0.4; 0.7 respectively in both biomarkers concentrations (CXCL13, anti-CarP) among age groups. There were significant differences between CXCL13 and disease duration (P value=0.05), while there were no significant differences between anti-CarP and disease duration (P value=0.2). There were no significant differences of concentration of ACCP, CXCL13 and anti-CarP according to DAS-ESR, at P value=0.2; 0.2 and 0.1 respectively. There were no significant differences between CXCL13 and anti-CarP in regard to CDAI, the means of CXCL13 in mild was 0.893±0.14, moderate 0.874±0.4and sever 0.963.1±0.9 at (P value =0.4), while The overall number of positive Anti-Carp patients is 22, with mild 5(22.7%), moderate 9(40.9%), and severe 8(36.4%) cases at p value=0.8 .
There were no significant differences among study parameters (CXCL13 and ACCP) in regard to treatment response, the means CXCL13 of good 0.899.5±0.60 and poor 0.940±0.1 at (P value =0.7).The means ACCP of good 73.8±9.2 and poor 73.6±15.2 at( P value =0.7).
In conclusion, the study has shown that the more common of RA patients were females.CXCL13, Anti-CarP, Anti-CCP, and RF levels with high significantly differ among rheumatoid arthritis patients and healthy groups.CXCL13 demonstrated good specificity and high sensitivity, while the AUC for CXCL13 was 0.88, these results suggest a superior role of CXCL13 positivity in diagnosis of RA. Anti-CarP antibodies demonstrated low sensitivity and high specificity. On the other hand, the AUC for anti-CarP antibodies was 0.67; these results suggest an additional role of anti-CarP positivity in the diagnosis of RA. There was a non-significant correlation between serum level of ACCP, CXCL13, Anti-CarP with DAS28-ESR and CDAI, so these biomarkers not usefulness in prediction of disease-severity. The serum levels of ACCP, CXCL13, Anti-CarP, did not significantly correlate with CDAI or DAS28-ESR, indicating that these biomarkers were not effective in predicting the severity of the disease